Related Experiment Video
Updated: Mar 22, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts
Yuqiao Sheng1,2,3, Kangdong Liu1,2,4, Qiong Wu1,4
1Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China.
Abstract:
Esophageal cancer is one of the least studied and deadliest cancers worldwide with a poor prognosis due to limited options for treatment. Chemotherapy agents such as the microtubule-targeting compounds are the mainstay of palliation for advanced esophageal cancer treatment. However, the toxicity and side effects of tubulin-binding agents (TBAs) have promoted the development of novel, more potent but less toxic TBAs. Herein, we identified 2-[4-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrazol-5-yl]-5-[(2-methylprop-2-en-1-yl)oxy] phenol (PPMP) as a novel TBA for esophageal cancer treatment. PPMP markedly inhibited tubulin polymerization, and decreased viability and anchorage-independent growth of esophageal cancer cell lines, effects that were accompanied by G2/M arrest and apoptosis. Importantly, we produced patient-derived esophageal cancer xenografts to evaluate the therapeutic effect of PPMP in a setting that best mimics the clinical context in patients with esophageal cancer. Overall, we identified PPMP as a novel microtubule-destabilizing compound and as a new therapeutic agent against esophageal carcinoma.
Insights
Researchers discovered a new compound, PPMP, that effectively targets esophageal cancer cells by disrupting microtubule polymerization. This novel agent shows promise as a less toxic, more potent treatment option for this deadly disease.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Esophageal cancer has a poor prognosis due to limited treatment options.
- Microtubule-targeting compounds are standard chemotherapy for advanced esophageal cancer.
- Existing tubulin-binding agents (TBAs) have significant toxicity, necessitating new drug development.
Purpose of the Study:
- To identify and characterize novel, less toxic tubulin-binding agents (TBAs) for esophageal cancer treatment.
- To evaluate the efficacy of a newly identified compound, PPMP, against esophageal cancer cells and in patient-derived xenografts.
Main Methods:
- In vitro assessment of PPMP's effect on tubulin polymerization and esophageal cancer cell lines.
- Analysis of cell cycle progression (G2/M arrest) and apoptosis induction by PPMP.
- Evaluation of PPMP's therapeutic effect using patient-derived esophageal cancer xenografts.
Main Results:
- PPMP significantly inhibited tubulin polymerization.
- PPMP reduced esophageal cancer cell viability and anchorage-independent growth.
- PPMP induced G2/M cell cycle arrest and apoptosis in cancer cells.
- PPMP demonstrated therapeutic efficacy in patient-derived xenografts, mimicking clinical settings.
Conclusions:
- PPMP is a novel microtubule-destabilizing compound.
- PPMP exhibits potent anti-cancer activity against esophageal carcinoma.
- PPMP represents a promising new therapeutic agent for esophageal cancer treatment.
More Related Videos
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules